Clearside Biomedical Inc Cash Flow Conversion Efficiency
Clearside Biomedical Inc cash flow conversion efficiency. Based on the latest financial reports, Clearside Biomedical Inc (CLSD) has a cash flow conversion efficiency ratio of 0.102x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.48 Million) by net assets ($-53.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Clearside Biomedical Inc (2012–2024)
Cash flow conversion efficiency of Clearside Biomedical Inc from 2012 to 2024. This chart illustrates how Clearside Biomedical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CLSD stock price for real-time trading data and today's change.
Clearside Biomedical Inc Cash Flow Conversion Ratio Explained
Clearside Biomedical Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Clearside Biomedical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clearside Biomedical Inc ranked by their cash flow conversion efficiency. Also see Clearside Biomedical Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Battery Metals Ltd
V:GBML
|
-0.020x |
|
NewGenIvf Group Limited Class A Ordinary Shares
NASDAQ:NIVF
|
-0.245x |
|
Candela Invest SA
BR:CAND
|
0.050x |
|
Lucapa Diamond Co Ltd
F:NHY
|
-0.007x |
|
Fonix Mobile plc
LSE:FNX
|
1.074x |
|
SRT Marine Systems plc
LSE:SRT
|
-0.305x |
|
Australian Bond Exchange Holdings Ltd
AU:ABE
|
0.350x |
|
Seeing Machines Limited
LSE:SEE
|
-0.731x |
Annual Cash Flow Conversion Efficiency for Clearside Biomedical Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Clearside Biomedical Inc from 2012 to 2024. Review how much free cash does Clearside Biomedical Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-38.85 Million | $-24.70 Million | 0.636x | -44.23% |
| 2023-12-31 | $-15.91 Million | $-18.14 Million | 1.140x | +190.45% |
| 2022-12-31 | $10.61 Million | $-13.37 Million | -1.260x | -345.81% |
| 2021-12-31 | $37.98 Million | $-10.73 Million | -0.283x | +81.12% |
| 2020-12-31 | $8.76 Million | $-13.12 Million | -1.497x | +38.29% |
| 2019-12-31 | $11.16 Million | $-27.07 Million | -2.426x | +27.65% |
| 2018-12-31 | $23.62 Million | $-79.20 Million | -3.353x | -40.57% |
| 2017-12-31 | $21.41 Million | $-51.08 Million | -2.385x | -652.72% |
| 2016-12-31 | $71.66 Million | $-22.71 Million | -0.317x | -183.57% |
| 2015-12-31 | $-36.66 Million | $-13.90 Million | 0.379x | -20.14% |
| 2014-12-31 | $-19.21 Million | $-9.12 Million | 0.475x | -25.44% |
| 2013-12-31 | $-10.74 Million | $-6.84 Million | 0.637x | +104.79% |
| 2012-12-31 | $239.00K | $-3.18 Million | -13.289x | -- |
About Clearside Biomedical Inc
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, whic… Read more